BIOCRYST PHARMACEUTICALS, INC. Inventory Valuation Reserves
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Inventory Valuation Reserves of $1.17 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Inventory, Net
us-gaap:InventoryValuationReserves · last filed 2026-08-05
- 2026-06-30: Inventory Valuation Reserves $1.17M.
- 2026-03-31: Inventory Valuation Reserves $799.00K.
- 2025-12-31: Inventory Valuation Reserves $775.00K.
- 2025-09-30: Inventory Valuation Reserves $1.66M.
| Period end | Inventory Valuation Reserves |
|---|---|
| 2026-06-30 | $1.17M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $799.00K 10-Q · filed 2026-05-06 |
| 2025-12-31 | $775.00K 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.66M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.91M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $2.08M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $2.65M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.75M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $1.60M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.60M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.60M 10-K · filed 2025-02-25 |
| 2023-09-30 | $1.35M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.42M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $1.41M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $1.18M 10-K · filed 2024-02-27 |
| 2022-09-30 | $245.00K 10-Q · filed 2022-11-04 |
| 2022-06-30 | $253.00K 10-Q · filed 2022-08-05 |
| 2022-03-31 | $253.00K 10-Q · filed 2022-05-09 |
| 2021-12-31 | $245.00K 10-K · filed 2023-02-27 |
| 2021-09-30 | $423.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $270.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $270.00K 10-Q · filed 2021-05-07 |
| 2020-12-31 | $270.00K 10-K · filed 2022-02-28 |
| 2019-12-31 | $276.00K 10-K · filed 2021-03-01 |
| 2013-12-31 | $4.24M 10-K · filed 2015-03-02 |
| 2012-12-31 | $4.24M 10-K · filed 2014-03-10 |
| 2012-09-30 | $3.98M 10-Q · filed 2012-11-08 |
| 2012-06-30 | $3.98M 10-Q · filed 2012-08-08 |
| 2011-12-31 | $4.62M 10-K · filed 2013-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |